Ajeet Kumar Gandhi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ajeet Kumar Gandhi has a total of 405 co-authors. Here are the top co-authors by number of shared publications:
Daya Nand Sharma
Department of Radiation Oncology, AIIMS, Bilaspur, Chhattisgarh, India
23 shared publicationsPramod Kumar Julka
All India Inst Med Sci, Dept Radiat Oncol, New Delhi, India
23 shared publicationsMadhup Rastogi
Department of Radiation Oncology, Dr Ram Manohar Lohia Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
20 shared publications- Rahat Hadi
Department of Radiation Oncology, Dr. Ram Manohar Lohia Institute of Medical Sciences, Lucknow, India
17 shared publications Goura Kishor Rath
DRBRAIRCH, NCI, AIIMS, New Delhi, India
16 shared publications- Satyajeet Rath
Department of Radiation Oncology, All India Institute of Medical Sciences, Rajkot, Gujarat, India
16 shared publications
Latest Publications
- Open Access
- 23 June 2026
- Published by Elsevier in SSRN Electronic Journal
Transition From 2D to Image-Guided Adaptive Brachytherapy for Cervical cancer in India: Clinical Impact of AROI-ESTRO GYN Teaching Courses
Background and Purpose Six annual teaching courses were conducted in India between 2017 and 2023, focusing on image-guided adaptive brachytherapy (IGABT) for cervical cancer. The course curriculum was developed as a collaborative initiative between the Association of Radiation Oncologists of India (AROI) and the European Society for Radiation Oncology (ESTRO). The present study reports the academic and clinical impact of these courses. Material and Methods A detailed online master survey of all participants (456 participants from 184 institutions) was conducted in 2023 to understand the impact of these courses on knowledge and practice. The outcomes were compared with pre-course surveys. Results Participants from 104 institutions responded to the master survey while 101 who continued to practice cervical cancer brachytherapy at the time of the survey were included. As per baseline pre-course surveys, imaging used routinely for brachytherapy planning was X-rays (25%), CT (75%) and MRI (10%). IC+IS applications and IGABT were used by 31% and 35% participants, respectively. In the master survey, improvement in knowledge and practice of IGABT was reported by 94% and 87% of respondents, respectively. Meaningful improvements were reported in implementation of critical processes like use of clinical drawings (33%), ultrasound guidance (17%), IC+IS applications (25%), target-volume delineation (38%) and volume-based prescription (35%). Frequent reasons cited for inability to implement and sustain these critical processes included large patient volume, lack of infrastructure, suboptimal human resources etc. Conclusion The survey results suggest that such teaching courses improve implementation of IGABT workflows for cervical cancer in clinical practice. Conference Presentation The outcome was presented in the Oral Proffered presentation at World Congress in Brachytherapy in 10-13 July 2024 at Maryland USA.
- 23 June 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessTransition From 2D to Image-Guided Adaptive Brachytherapy for Cervical cancer in India: Clinical Impact of AROI-ESTRO GYN Teaching Courses
Background and Purpose Six annual teaching courses were conducted in India between 2017 and 2023, focusing on image-guided adaptive brachytherapy (IGABT) for cervical cancer. The course curriculum was developed as a collaborative initiative between the Association of Radiation Oncologists of India (AROI) and the European Society for Radiation Oncology (ESTRO). The present study reports the academic and clinical impact of these courses. Material and Methods A detailed online master survey of all participants (456 participants from 184 institutions) was conducted in 2023 to understand the impact of these courses on knowledge and practice. The outcomes were compared with pre-course surveys. Results Participants from 104 institutions responded to the master survey while 101 who continued to practice cervical cancer brachytherapy at the time of the survey were included. As per baseline pre-course surveys, imaging used routinely for brachytherapy planning was X-rays (25%), CT (75%) and MRI (10%). IC+IS applications and IGABT were used by 31% and 35% participants, respectively. In the master survey, improvement in knowledge and practice of IGABT was reported by 94% and 87% of respondents, respectively. Meaningful improvements were reported in implementation of critical processes like use of clinical drawings (33%), ultrasound guidance (17%), IC+IS applications (25%), target-volume delineation (38%) and volume-based prescription (35%). Frequent reasons cited for inability to implement and sustain these critical processes included large patient volume, lack of infrastructure, suboptimal human resources etc. Conclusion The survey results suggest that such teaching courses improve implementation of IGABT workflows for cervical cancer in clinical practice. Conference Presentation The outcome was presented in the Oral Proffered presentation at World Congress in Brachytherapy in 10-13 July 2024 at Maryland USA.
- Open Access
- 1 January 2026
- Published by Wolters Kluwer Health in Journal of Cancer Research and Therapeutics
- Vol. 22 (1) , 84-89
Doses to pelvic bone marrow from intracavitary brachytherapy in carcinoma cervix: A dosimetric study
Purpose: Current dose–volume constraints for pelvic bone marrow (PBM) sparing in radiotherapy for locally advanced cervical carcinoma (LACC) typically do not account for the dose contribution from intracavitary brachytherapy (ICBT). This study aimed to quantify the radiation dose received by PBM during ICBT. Materials and Methods: This dosimetric analysis utilized computed tomography (CT) data from 15 patients with LACC treated with ICBT. Each patient received 3 weekly fractions of 7 Gy. PBM was delineated from the sacrum to the ischial tuberosities across all 45 CT sessions (three per patient). Two treatment plans were generated—Plan A (high-risk clinical target volume [HR-CTV]–based) and Plan B (Point A–based)—yielding 90 plans in total. PBM volumes receiving ≥1.5 Gy (V1.5), 1 Gy (V1), 0.75 Gy (V0.75), and 0.5 Gy (V0.5) were recorded. Results: Out of 15 patients, 9 were diagnosed with stage IIB and 6 with stage IIIB (FIGO 2018). The median HR-CTV volume was 19.2 cc (range: 17–35.8 cc), with a median D90 per fraction of 6.9 Gy. The median PBM volume was 927.5 cc (range: 620.8–999.3 cc). For Plan A, the median V1.5, V1, V0.75, and V0.5 were 2.7%, 13%, 24.98%, and 53.69%, respectively, compared to 3.89%, 21.82%, 40.3%, and 67.36% for Plan B. Mean values for Plan A vs. Plan B were as follows: V1.5 (2.89% ±2.6% vs. 5.15% ± 3.57%, P = 0.058), V1 (14.14% ±9.67% vs. 20.6% ±7.82%, P = 0.054), V0.75 (29.22% ±14.99% vs. 39.47% ±11.36%, P = 0.045), and V0.5 (53.2% ±17.1% vs. 64.39% ±12.33%, P = 0.049). Conclusion: ICBT contributes a measurable dose to the PBM, with approximately 15–20% of PBM receiving around 1 Gy per 7 Gy fraction.
- 1 January 2026
- Published by Wolters Kluwer Health in Journal of Cancer Research and Therapeutics
- Vol. 22 (1) , 84-89
Open AccessDoses to pelvic bone marrow from intracavitary brachytherapy in carcinoma cervix: A dosimetric study
Purpose: Current dose–volume constraints for pelvic bone marrow (PBM) sparing in radiotherapy for locally advanced cervical carcinoma (LACC) typically do not account for the dose contribution from intracavitary brachytherapy (ICBT). This study aimed to quantify the radiation dose received by PBM during ICBT. Materials and Methods: This dosimetric analysis utilized computed tomography (CT) data from 15 patients with LACC treated with ICBT. Each patient received 3 weekly fractions of 7 Gy. PBM was delineated from the sacrum to the ischial tuberosities across all 45 CT sessions (three per patient). Two treatment plans were generated—Plan A (high-risk clinical target volume [HR-CTV]–based) and Plan B (Point A–based)—yielding 90 plans in total. PBM volumes receiving ≥1.5 Gy (V1.5), 1 Gy (V1), 0.75 Gy (V0.75), and 0.5 Gy (V0.5) were recorded. Results: Out of 15 patients, 9 were diagnosed with stage IIB and 6 with stage IIIB (FIGO 2018). The median HR-CTV volume was 19.2 cc (range: 17–35.8 cc), with a median D90 per fraction of 6.9 Gy. The median PBM volume was 927.5 cc (range: 620.8–999.3 cc). For Plan A, the median V1.5, V1, V0.75, and V0.5 were 2.7%, 13%, 24.98%, and 53.69%, respectively, compared to 3.89%, 21.82%, 40.3%, and 67.36% for Plan B. Mean values for Plan A vs. Plan B were as follows: V1.5 (2.89% ±2.6% vs. 5.15% ± 3.57%, P = 0.058), V1 (14.14% ±9.67% vs. 20.6% ±7.82%, P = 0.054), V0.75 (29.22% ±14.99% vs. 39.47% ±11.36%, P = 0.045), and V0.5 (53.2% ±17.1% vs. 64.39% ±12.33%, P = 0.049). Conclusion: ICBT contributes a measurable dose to the PBM, with approximately 15–20% of PBM receiving around 1 Gy per 7 Gy fraction.
- Open Access
- 11 December 2025
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 215, 111330
ESMO-ESTRO consensus statements on the safety of combining radiotherapy with CDK4/6, HER2, PARP, or mTOR inhibitors
- 11 December 2025
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 215, 111330
Open AccessESMO-ESTRO consensus statements on the safety of combining radiotherapy with CDK4/6, HER2, PARP, or mTOR inhibitors
- 29 November 2025
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 125 (2) , 444-453
Five-Year Outcomes of Moderately Hypofractionated Whole Pelvic Radiation Therapy with Concurrent Chemotherapy and Image Guided High Dose Rate Brachytherapy for Locally Advanced Cervical Carcinoma
- 29 November 2025
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 125 (2) , 444-453
Five-Year Outcomes of Moderately Hypofractionated Whole Pelvic Radiation Therapy with Concurrent Chemotherapy and Image Guided High Dose Rate Brachytherapy for Locally Advanced Cervical Carcinoma
- Open Access
- 5 August 2025
- Published by Elsevier in Radiology Case Reports
- Vol. 20 (10) , 5296-5299
Rare case of Infiltrative multifocal Ewing sarcoma presenting as neck mass
- 5 August 2025
- Published by Elsevier in Radiology Case Reports
- Vol. 20 (10) , 5296-5299
Open AccessRare case of Infiltrative multifocal Ewing sarcoma presenting as neck mass
- Open Access
- 1 January 2025
- Published by Termedia Sp. z.o.o. in Journal of Contemporary Brachytherapy
- Vol. 17 (5) , 293-299
Clinical and dosimetric outcomes of carcinoma cervix patients treated with MRI only at first fraction, followed by CT-based image-guided brachytherapy for subsequent fractions
Introduction Magnetic resonance (MRI)-based image-guided brachytherapy (IGBT) is the gold standard technique for carcinoma cervix. We aimed to evaluate doses to target and organs at risk (OARs), and report clinical outcomes of locally advanced carcinoma cervix (LACC) patients treated with a...
- 1 January 2025
- Published by Termedia Sp. z.o.o. in Journal of Contemporary Brachytherapy
- Vol. 17 (5) , 293-299
Open AccessClinical and dosimetric outcomes of carcinoma cervix patients treated with MRI only at first fraction, followed by CT-based image-guided brachytherapy for subsequent fractions
Introduction Magnetic resonance (MRI)-based image-guided brachytherapy (IGBT) is the gold standard technique for carcinoma cervix. We aimed to evaluate doses to target and organs at risk (OARs), and report clinical outcomes of locally advanced carcinoma cervix (LACC) patients treated with a...
- 1 January 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 11 (11) , e2400349
Multicentric Cross-Sectional Survey to Assess the Variation of Fractionation Strategies Used in the Management of Head and Neck Cancers in the Asian Region (INNOCENCE-ASIA)
PURPOSE: Head and neck cancers (HNCs) are in general treated with conventional fractionation regimen of 1.8-2 Gy per fraction. Altered fractionation (ALFT) strategies such as hypofractionation radiotherapy (HYPO-RT), accelerated fractionation radiotherapy (AFRT), and hyperfractionation radiotherapy (HFRT) have not been practiced uniformly across centers in different parts of the world. Countries in Asia share common cancer demographics, and we designed this survey for Federation of Asian Radiation Oncology (FARO) member countries to understand the usage and challenges in the delivery of ALFT in HNCs. MATERIALS AND METHODS: A 21-point electronic survey (Federation of Asian Radiation Oncology Research Network [FERN]-S-005) was designed by the FERN and was circulated through the FARO research secretariat to the FARO council member countries and the responses were collected between August and November 2023. RESULTS: Twelve of 14 member countries (85.7%) responded to the survey. Twenty-seven responses were received and 78% of the respondents belonged to government/teaching academic institute. 4/27 (14.8%) reported never using HYPO-RT for any of the clinical subsite of HNCs, while the majority (85.2%) used it for glottic cancers and 22% also used it for postoperative setting. Majority (77.7%) used a fractionation schedule with dose per fraction ranging between 2.2 and 2.5 Gy. 6/27 (22.2%) used AFRT for definitive setting and five of these also used concurrent chemoradiotherapy. 4/27 (14.8%) centers reported using HFRT. The most common reason (62.9%) for the limited usage of AFRT/HFRT was reported to be logistical, such as unavailability of machine slots, patient load, and so on. CONCLUSION: The result of the survey suggests that among the ALFT strategies for HNCs, HYPO-RT schedules have common interest and feasibility among the FARO member countries and also highlights the challenges in the delivery of AFRT/HFRT in the Asian region.
- 1 January 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 11 (11) , e2400349
Multicentric Cross-Sectional Survey to Assess the Variation of Fractionation Strategies Used in the Management of Head and Neck Cancers in the Asian Region (INNOCENCE-ASIA)
PURPOSE: Head and neck cancers (HNCs) are in general treated with conventional fractionation regimen of 1.8-2 Gy per fraction. Altered fractionation (ALFT) strategies such as hypofractionation radiotherapy (HYPO-RT), accelerated fractionation radiotherapy (AFRT), and hyperfractionation radiotherapy (HFRT) have not been practiced uniformly across centers in different parts of the world. Countries in Asia share common cancer demographics, and we designed this survey for Federation of Asian Radiation Oncology (FARO) member countries to understand the usage and challenges in the delivery of ALFT in HNCs. MATERIALS AND METHODS: A 21-point electronic survey (Federation of Asian Radiation Oncology Research Network [FERN]-S-005) was designed by the FERN and was circulated through the FARO research secretariat to the FARO council member countries and the responses were collected between August and November 2023. RESULTS: Twelve of 14 member countries (85.7%) responded to the survey. Twenty-seven responses were received and 78% of the respondents belonged to government/teaching academic institute. 4/27 (14.8%) reported never using HYPO-RT for any of the clinical subsite of HNCs, while the majority (85.2%) used it for glottic cancers and 22% also used it for postoperative setting. Majority (77.7%) used a fractionation schedule with dose per fraction ranging between 2.2 and 2.5 Gy. 6/27 (22.2%) used AFRT for definitive setting and five of these also used concurrent chemoradiotherapy. 4/27 (14.8%) centers reported using HFRT. The most common reason (62.9%) for the limited usage of AFRT/HFRT was reported to be logistical, such as unavailability of machine slots, patient load, and so on. CONCLUSION: The result of the survey suggests that among the ALFT strategies for HNCs, HYPO-RT schedules have common interest and feasibility among the FARO member countries and also highlights the challenges in the delivery of AFRT/HFRT in the Asian region.
- Open Access
- 1 October 2024
- Published by Wolters Kluwer Health in Journal of Cancer Research and Therapeutics
- Vol. 20 (6) , 1674-1676
Unlocking the “Golden” potential of brachytherapy at the nanoscale: Is the era of nano-brachytherapy near?
- 1 October 2024
- Published by Wolters Kluwer Health in Journal of Cancer Research and Therapeutics
- Vol. 20 (6) , 1674-1676
Open AccessUnlocking the “Golden” potential of brachytherapy at the nanoscale: Is the era of nano-brachytherapy near?
- Open Access
- 1 July 2024
- Published by Wolters Kluwer Health in Journal of Cancer Research and Therapeutics
- Vol. 20 (5) , 1557-1563
Pattern of care and clinical outcome of patients with carcinoma endometrium and the impact of central histopathological review on management: A tertiary cancer centre experience
Purpose/Objective: Endometrial carcinoma (EC) is the third most common gynecological malignancy in India. Recent PORTEC-3 analysis emphasized the role of central histopathological review. We aimed to retrospectively analyze the demographic and histopathological characteristics of EC patients treated at our institute and assess the impact of the central histopathological review on management and also analyze clinical outcomes in this cohort of patients. Materials and Methods: Data of 75 EC patients treated at our center between 2013 and 2022 were retrieved from our departmental archives. Patients were analyzed for demographic details, histopathological findings, details of surgery and histopathology (HPE), results of a review of HPE, adjuvant treatment details, and clinical outcomes. All patients with HPE outside of our institute were reviewed at our center prior to initiation of treatment. In cases of discordance, patients were discussed in the multidisciplinary tumor board for the final treatment decisions. Patients were staged as per International Federation of Gynaecology and Obstetrics 2018. Result: The median age was 57 years (range: 37-74 years). Twenty-seven patients with HPE reported from the outside center were reviewed at our institute and changes were observed in 26 patients (96.3%). HPE review changes were observed in terms of histological grade, histological type, myometrial invasion, and lymph node involvement in five (18.5%), three (11.1%), seven (25.9%), and three (42.8%), respectively. HPE review leads to changes in the management of 19/26 patients. Stage distribution was I: II: III in 48 (64%): 9 (13.3%): 18 (24%) patients, respectively. The median external beam radiotherapy dose was 50 Gray (range: 45-50.4 Gray at 1.8-2 Gray per fraction). The median brachytherapy dose for patients treated with brachytherapy alone was 7 Gray each for three sessions and in combination with EBRT was 6 Gray each in two sessions. At a median follow-up of 51 months (range: 6-116 months), seven (9.3%) patients developed distant metastasis, two (2.7%) patients had local plus distant metastasis, and two (2.7%) patients had local recurrence. The overall survival and disease-free survival rates at 3 years were 93.5% and 86.7%, respectively. Conclusion: EC patients treated at our center have excellent local control rates with a combination of external beam radiotherapy and brachytherapy. The central histopathological review may result in changes impacting patient management and should be routinely done prior to initiation of treatment in EC.
- 1 July 2024
- Published by Wolters Kluwer Health in Journal of Cancer Research and Therapeutics
- Vol. 20 (5) , 1557-1563
Open AccessPattern of care and clinical outcome of patients with carcinoma endometrium and the impact of central histopathological review on management: A tertiary cancer centre experience
Purpose/Objective: Endometrial carcinoma (EC) is the third most common gynecological malignancy in India. Recent PORTEC-3 analysis emphasized the role of central histopathological review. We aimed to retrospectively analyze the demographic and histopathological characteristics of EC patients treated at our institute and assess the impact of the central histopathological review on management and also analyze clinical outcomes in this cohort of patients. Materials and Methods: Data of 75 EC patients treated at our center between 2013 and 2022 were retrieved from our departmental archives. Patients were analyzed for demographic details, histopathological findings, details of surgery and histopathology (HPE), results of a review of HPE, adjuvant treatment details, and clinical outcomes. All patients with HPE outside of our institute were reviewed at our center prior to initiation of treatment. In cases of discordance, patients were discussed in the multidisciplinary tumor board for the final treatment decisions. Patients were staged as per International Federation of Gynaecology and Obstetrics 2018. Result: The median age was 57 years (range: 37-74 years). Twenty-seven patients with HPE reported from the outside center were reviewed at our institute and changes were observed in 26 patients (96.3%). HPE review changes were observed in terms of histological grade, histological type, myometrial invasion, and lymph node involvement in five (18.5%), three (11.1%), seven (25.9%), and three (42.8%), respectively. HPE review leads to changes in the management of 19/26 patients. Stage distribution was I: II: III in 48 (64%): 9 (13.3%): 18 (24%) patients, respectively. The median external beam radiotherapy dose was 50 Gray (range: 45-50.4 Gray at 1.8-2 Gray per fraction). The median brachytherapy dose for patients treated with brachytherapy alone was 7 Gray each for three sessions and in combination with EBRT was 6 Gray each in two sessions. At a median follow-up of 51 months (range: 6-116 months), seven (9.3%) patients developed distant metastasis, two (2.7%) patients had local plus distant metastasis, and two (2.7%) patients had local recurrence. The overall survival and disease-free survival rates at 3 years were 93.5% and 86.7%, respectively. Conclusion: EC patients treated at our center have excellent local control rates with a combination of external beam radiotherapy and brachytherapy. The central histopathological review may result in changes impacting patient management and should be routinely done prior to initiation of treatment in EC.